Skip to main content
. 2015 Feb 10;6(10):7644–7656. doi: 10.18632/oncotarget.3223

Figure 5. Knockdown of HDAC9 inhibits the activity of the EGFR/AKT/ERK pathway.

Figure 5

(A) The expression of p-EGFR, EGFR, p-AKT, AKT, p-ERK1/2 and ERK1/2 in HDAC9-knockdown U87 cells was measured by western blot assay. (B) Representative blots showing the expression of p-EGFR, EGFR, p-AKT, AKT, p-ERK1/2 and ERK1/2 in HDAC9-knockdown LN229 cells. (C) The expression of p-EGFR, EGFR, p-AKT, AKT, p-ERK1/2 and ERK1/2 in tumor xenografts was measured by western blot.